23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Cytek Biosciences, Inc. › 2025-2026

Cytek Biosciences, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Cytek Biosciences, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 176Asset managers, any item
  • 1,246Fund votes
  • June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 5 items on Cytek Biosciences, Inc.’s Form 8-K, filed June 16, 2026: 3 elected · 2 approved.

Dissent

Significant dissent: 1 director (24.2% against).

Notable dissent: 1 director (10.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Cytek Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Cytek Biosciences, Inc.

These tallies are Cytek Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Cytek Biosciences, Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Vera Imper, Ph.D. 64,769,976---- 20,723,47725,668,037 76%Elected—
Elect Director: Glenn P. Muir 79,599,103---- 5,894,35025,668,037 93%Elected—
Elect Director: Ming Yan, Ph.D. 76,741,063---- 8,752,39025,668,037 90%Elected—
2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025 84,794,380677,86121,212 --25,668,037 99.2%Approved—
3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 110,533,253479,883148,354 ---- 99.6%Approved—

Source: Cytek Biosciences, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.

How asset managers voted at the Cytek Biosciences, Inc. 2025-2026 meeting

176 asset managers disclosed a vote on at least one Cytek Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Glenn P. Muir

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 79,599,103WITHHELD: 5,894,350
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Glenn P. Muir

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Glenn P. Muir”): 79,599,103 for, 5,894,350 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 32,417,672 for, 801,219 withheld, 2,017,909 abstained.

FOR
FOR: 32,417,672ABSTAIN: 2,017,909WITHHOLD: 801,219
Largest asset managers voting on “To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,318,1360 620For
Fidelity2,553,6040 00For
TRUST FOR PROFESSIONAL MANAGERS00 2,017,8470Abstain
Royce1,628,0950 00For
State Street1,213,7620 00For
Brown Capital Management Mutual Funds973,7070 00For
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.00 0801,219Withhold
Dimensional785,1500 00For
Russell Investments597,7860 00For
Equitable283,0940 00For
American Century281,5780 00For
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National194,8090 00For
Columbia Threadneedle167,5570 00For
Lincoln Financial167,1070 00For
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya134,5980 00For
Prudential/PGIM109,5520 00For
AIG/SunAmerica98,4970 00For
BNY Mellon93,5160 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Ming Yan, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 76,741,063WITHHELD: 8,752,390
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Ming Yan, Ph.D.

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Ming Yan, Ph.D.”): 76,741,063 for, 8,752,390 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 31,527,416 for, 1,663,325 withheld, 2,046,059 abstained.

FOR
FOR: 31,527,416ABSTAIN: 2,046,059WITHHOLD: 1,663,325
Largest asset managers voting on “To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,284,7480 9233,359For
Fidelity2,553,6040 00For
TRUST FOR PROFESSIONAL MANAGERS00 2,017,8470Abstain
Royce1,628,0950 00For
State Street1,212,2520 01,510For
Brown Capital Management Mutual Funds973,7070 00For
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.00 0801,219Withhold
Dimensional00 0785,150Withhold
Russell Investments597,7860 00For
Equitable283,0940 00For
American Century281,5780 00For
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National166,6890 28,1200Mixed
Columbia Threadneedle167,5570 00For
Lincoln Financial157,8310 09,276Mixed
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya134,5980 00For
Prudential/PGIM96,2570 013,295Mixed
AIG/SunAmerica98,4970 00For
BNY Mellon93,5160 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Vera Imper, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 64,769,976WITHHELD: 20,723,477
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Vera Imper, Ph.D.

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Vera Imper, Ph.D.”): 64,769,976 for, 20,723,477 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 28,289,297 for, 4,625,628 withheld, 2,321,875 abstained.

FOR
FOR: 28,289,297ABSTAIN: 2,321,875WITHHOLD: 4,625,628
Largest asset managers voting on “To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,267,0020 17151,025For
Fidelity2,553,5040 0100For
TRUST FOR PROFESSIONAL MANAGERS00 2,017,8470Abstain
Royce1,628,0950 00For
State Street1,210,7500 03,012For
Brown Capital Management Mutual Funds00 0973,707Withhold
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.00 0801,219Withhold
Dimensional00 0785,150Withhold
Russell Investments00 0597,786Withhold
Equitable170,7880 0112,306Mixed
American Century00 0281,578Withhold
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National00 194,8090Abstain
Columbia Threadneedle167,5570 00For
Lincoln Financial82,0000 085,107Mixed
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya00 0134,598Withhold
Prudential/PGIM96,2570 013,295Mixed
AIG/SunAmerica00 098,497Withhold
BNY Mellon00 093,516Withhold

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.2% Approved · of votes cast

FOR 99.2%
FOR: 84,794,380AGAINST: 677,861

Prior year: 93.1% for (June 18, 2025 meeting) ▲ 6.1 pts

Details: description as filed, official tally, votes by 176 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers for the year ended December 31, 2025, as set forth in our proxy statement.

Cytek Biosciences, Inc.’s own tally for this item (“2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025”): 84,794,380 for, 677,861 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025 was approved based on the following results of voting:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers for the year en” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,318,1944 00For
Fidelity2,553,6040 00For
TRUST FOR PROFESSIONAL MANAGERS2,017,8470 00For
Royce1,628,0950 00For
State Street1,213,7620 00For
Brown Capital Management Mutual Funds973,7070 00For
RBB FUND, INC.920,0360 00For
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
Dimensional785,1500 00For
Russell Investments597,7860 00For
Equitable283,0940 00For
American Century0281,578 00Against
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National194,8090 00For
Columbia Threadneedle167,5570 00For
Lincoln Financial167,1070 00For
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya134,5980 00For
Prudential/PGIM109,5520 00For
AIG/SunAmerica98,4970 00For
BNY Mellon93,5160 00For

Fund voting reports, all 58 managers: 35,082,545 for, 281,582 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 138 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers for the year en” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Topline Capital Management, LLC7,141,1840 00For
HHLR ADVISORS, LTD.6,657,0300 00For
Boston Partners5,665,8380 00For
BlackRock3,850,2390 00For
State Street3,482,8300 00For
GEODE CAPITAL MANAGEMENT, LLC2,775,4360 00For
BROWN CAPITAL MANAGEMENT LLC1,394,6980 00For
Charles Schwab1,106,3530 00For
Russell Investments1,099,5530 00For
Vanguard772,6180 00For
Northern Trust751,7270 00For
MELLON INVESTMENTS Corp633,6390 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC598,6530 00For
PRINCIPAL GLOBAL INVESTORS534,0820 00For
Goldman Sachs343,1530 00For
BANK OF AMERICA NA315,2130 00For
American Century0281,766 00Against
Dimensional258,4250 00For
JACOBS LEVY EQUITY MANAGEMENT, INC257,2920 00For
Nuveen247,0660 00For
Invesco210,1490 00For
ACADIAN ASSET MANAGEMENT LLC197,8630 00For
Fidelity191,1720 00For
Legal & General Investment Management America Inc0167,321 00Against
AQR158,5430 00For

Institutional-manager reports, all 138 managers: 41,060,280 for, 494,797 against, 11,449 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 110,533,253AGAINST: 479,883

Prior year: 92.6% for (June 18, 2025 meeting) ▲ 7.0 pts

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Cytek Biosciences, Inc.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December”): 110,533,253 for, 479,883 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 35,242,668 for, 2,641 against.

FOR
FOR: 35,242,668AGAINST: 2,641
Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE ” at Cytek Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock12,354,6590 00For
Vanguard7,318,1952 00For
Fidelity2,553,6040 00For
TRUST FOR PROFESSIONAL MANAGERS2,017,8470 00For
Royce1,628,0950 00For
State Street1,213,114648 00For
Brown Capital Management Mutual Funds973,7070 00For
Charles Schwab911,2030 00For
Goldman Sachs845,0790 00For
RBB FUND, INC.801,2190 00For
Dimensional785,1500 00For
Russell Investments597,7860 00For
Equitable283,0940 00For
American Century281,5780 00For
TIAA242,3550 00For
QUANTITATIVE MASTER SERIES LLC199,1550 00For
Jackson National194,8090 00For
Columbia Threadneedle167,5570 00For
Lincoln Financial167,1070 00For
JPMorgan157,6210 00For
Invesco151,3810 00For
Voya134,5980 00For
Prudential/PGIM109,5520 00For
AIG/SunAmerica98,4970 00For
BNY Mellon93,5160 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Largest Cytek Biosciences, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 129,142,587 shares outstanding at the time of that meeting.

Fund voting reports: top Cytek Biosciences, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 9.57%
2Vanguard 5.67%
3Fidelity 1.98%
4TRUST FOR PROFESSIONAL MANAGERS 1.56%
5Royce 1.26%
6State Street 0.94%
7Brown Capital Management Mutual Funds 0.75%
8RBB FUND, INC. 0.71%
9Charles Schwab 0.71%
10Goldman Sachs 0.65%
Institutional-manager reports: top Cytek Biosciences, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1Topline Capital Management, LLC 5.53%
2HHLR ADVISORS, LTD. 5.15%
3Boston Partners 4.39%
4BlackRock 2.98%
5State Street 2.70%
6GEODE CAPITAL MANAGEMENT, LLC 2.15%
7BROWN CAPITAL MANAGEMENT LLC 1.08%
8Charles Schwab 0.86%
9Russell Investments 0.85%
10Vanguard 0.60%

Reported Cytek Biosciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Cytek Biosciences, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock17,007,269 13.17%Form 13F, quarter ended March 31, 2026
Entities affiliated with BlackRock, Inc.16,531,858 12.80%Proxy statement (DEF 14A), proxy filed April 28, 2026
Entities affiliated with The Vanguard Group7,765,138 6.01%Proxy statement (DEF 14A), proxy filed April 28, 2026
Boston Partners7,635,145 5.91%Schedule 13G, filed August 4, 2026
Vanguard Group7,475,477 5.79%Form 13F, quarter ended March 31, 2026
Entities affiliated with Topline Capital Partners, LP6,780,847 5.25%Proxy statement (DEF 14A), proxy filed April 28, 2026
Wenbin Jiang, Ph.D.6,767,890 5.24%Proxy statement (DEF 14A), proxy filed April 28, 2026
Entities affiliated with Hillhouse Investment Management, Ltd.6,657,030 5.15%Proxy statement (DEF 14A), proxy filed April 28, 2026
Millennium Management6,291,798 4.87%Form 13F, quarter ended March 31, 2026
Ming Yan, Ph.D.5,389,900 4.17%Proxy statement (DEF 14A), proxy filed April 28, 2026

Percentages above are of 129,142,587 shares outstanding, as reported by Cytek Biosciences, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Cytek Biosciences, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 176 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,246 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers… — Cytek Biosciences, Inc.'s filing reports the proposal as approved, with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Cytek Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cytek Biosciences, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Cytek Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Cytek Biosciences (CTKB) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytek-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.